Renita Bhamrah, PhD, Pramod Kumar Julka, MD, Omana Nair, PhD, Rajinder Parshad, MS, Siddhartha Dattagupta, MD, Ranju Ralhan, PhD, Sadanand Dwivedi, PhD, Darpreet Singh Bhamrah, MS, Guresh Kumar, PhD, Sanjay Gupta, M Pharm, Gaurav Dhawan, MBBS, Goura Kishor Rath, MD. |
Abstract:
We studied the prognostic impact of EGFR positivity in Indian scenario and its correlation with known prognostic markers such as Estrogen receptor (ER) and HER-2/ neu oncogene. 210 women aged less than 70 years with histopathologically proven carcinoma breast and having ambulatory general condition were included in the study. EGFR, Her–2/neu and ER expressions were evaluated immunohistochemically. Of the 210 patients, the EGFR, ER and HER-2/neu expressions were positive in 87 (41%), 139 (66%) and 60 (29%) patients respectively. EGFR had a positive correlation with systemic recurrence and inverse correlation with overall survival of the patient. In multivariate analysis it was observed that EGFR and node positivity were significant factors for overall survival and disease free survival. Our study reveals that expression of EGFR may serve as a prognostic indicator for poor survival in breast cancer patients.
KEYWORDS: Breast Cancer, Prognostic Markers, EGFR, HER-2/neu, ER
|